Moderna (NASDAQ:MRNA) Reaches New 1-Year Low Following Analyst Downgrade

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) hit a new 52-week low during trading on Monday after Barclays lowered their price target on the stock from $125.00 to $111.00. Barclays currently has an overweight rating on the stock. Moderna traded as low as $45.44 and last traded at $45.44, with a volume of 945656 shares. The stock had previously closed at $46.83.

A number of other brokerages have also commented on MRNA. Deutsche Bank Aktiengesellschaft raised Moderna from a "sell" rating to a "hold" rating and decreased their price objective for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Jefferies Financial Group decreased their target price on shares of Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a research report on Tuesday, October 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a report on Friday. Hsbc Global Res upgraded Moderna from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 28th. Finally, Piper Sandler reduced their price target on Moderna from $157.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Moderna has an average rating of "Hold" and an average target price of $93.18.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 1,321 shares of the company's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO James M. Mock sold 715 shares of the firm's stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,930 shares of company stock valued at $217,170. 15.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Moderna

Hedge funds have recently modified their holdings of the business. Janney Montgomery Scott LLC increased its position in Moderna by 38.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 14,373 shares of the company's stock valued at $1,532,000 after purchasing an additional 4,003 shares during the period. Empowered Funds LLC increased its position in shares of Moderna by 26.8% during the first quarter. Empowered Funds LLC now owns 4,276 shares of the company's stock worth $456,000 after buying an additional 904 shares during the period. Atomi Financial Group Inc. bought a new position in Moderna during the first quarter worth $225,000. Sei Investments Co. lifted its holdings in Moderna by 16.4% in the first quarter. Sei Investments Co. now owns 84,910 shares of the company's stock valued at $9,048,000 after buying an additional 11,977 shares during the period. Finally, Meeder Advisory Services Inc. acquired a new position in Moderna in the first quarter valued at $206,000. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Down 8.7 %

The company has a quick ratio of 3.92, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The stock's 50-day simple moving average is $61.85 and its 200 day simple moving average is $99.09. The firm has a market cap of $16.43 billion, a P/E ratio of -7.28 and a beta of 1.69.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm's revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.39) EPS. As a group, research analysts forecast that Moderna, Inc. will post -9.89 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.